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Tumour-associated changes have been observed in the circulating nucleic acids of cancer patients and have been proposed to be
useful for the detection and monitoring of cancers. In this review, different approaches for detecting tumour-associated nucleic acids
in the circulation and their potential applications as tumour markers are discussed.
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Despite the advances in anticancer therapies, cancer remains a
leading cause of death in developed countries. For most cancers,
the extent of disease at the time of diagnosis is an important factor
for determining treatment outcome. In this regard, tumour
markers have been developed for the purpose of screening for
early malignant diseases. Besides, they are also valuable in
monitoring cancer progression as well as prognostication. Existing
markers are mainly proteins produced by tumour cells. Unfortu-
nately, only a subset of cancers would secrete specific proteins that
can be used as tumour markers. In contrast to tumour-associated
proteins, genetic aberrations are frequently observed in cancers
and some of these changes are believed to be directly involved in
carcinogenesis. With the developments of molecular techniques,
such changes can also be detected in the plasma or serum of cancer
patients and, thus, may open up the potential of utilising
circulating nucleic acids as a new generation of tumour markers.
This review summarises the different approaches for detecting
tumour-associated nucleic acids in the circulation and their
potential applications as tumour markers.
APPROACHES FOR DETECTING CANCER-ASSOCIATED
CHANGES IN CIRCULATING NUCLEIC ACIDS
Level of total circulating DNA
The existence of extracellular nucleic acids in the circulation was
first reported by Mandel and Metais in 1948. However, owing to
the technological limitations at that time, further development
came only after 30 years when Leon et al demonstrated that cancer
patients had much higher circulating DNA concentrations than
those suffering from non-malignant diseases (Leon et al, 1977).
Moreover, they showed that, in some cases, the levels of circulating
DNA would decrease after successful anticancer therapy (Leon
et al, 1977). These interesting findings have suggested the potential
application of circulating cell-free DNA level as a surrogate marker
for cancers. Recently, Gautschi et al (2004) demonstrated that
plasma DNA level was significantly associated with cancer stage in
patients with non-small-cell lung cancers. Patients with more
advanced disease had significantly higher levels of circulating DNA
(Gautschi et al, 2004). In addition, they also showed that plasma
DNA levels were of prognostic value for predicting survival in
patients undergoing chemotherapy. Patients with higher circulat-
ing DNA levels, either at baseline or after treatment, had
significantly reduced probability of long-term survival (Gautschi
et al, 2004). Interestingly, in a prospective study by Gormally et al
(2004), who followed up more than 500000 healthy individuals
from 22 centres, the elevation of circulating DNA level was shown
to be a risk factor for future development of leukaemia. Among
these over 500000 subjects, 359 of them developed cancers after a
mean follow-up of 89 months. The plasma DNA levels of those
subjects who subsequently developed cancers were compared to
the levels of 776 matched subjects who had not developed cancer,
and it was demonstrated that subjects with elevated plasma DNA at
baseline had increased risk of developing leukaemia in the next 36
months (Gormally et al, 2004).
The precise mechanisms leading to the elevated plasma
DNA levels in cancer patients are not clear. One hypothesis is
the direct release of tumoral DNA into the blood from the rapidly
turning-over cancer cells. Diagnostically, the elevation of circulat-
ing DNA is not specific for malignant conditions and plasma
DNA levels are also increased in other physiological and disease
conditions, for example pregnancy and trauma. Thus, methods for
the detection of tumour-specific DNA changes have been
developed.
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Mutations in oncogenes and tumour suppressor genes are
commonly detected in cancers and these changes are important
in the pathogenesis of cancers. Therefore, such mutations can be
recognised as a signature of tumour-derived DNA. In 1994,
Sorenson et al (1994) detected KRAS gene mutations in the plasma
and tumours of three patients suffering from pancreatic cancer.
Their findings provided direct evidence for the presence of
tumour-derived DNA in the circulation of cancer patients.
Recently, studies have also reported that tumour-associated
mutations could be found in the plasma/serum of individuals
exposed to carcinogens, and the presence of such mutations in the
circulation may indicate increased risk of developing cancers
(Gormally et al, 2006; Hagiwara et al, 2006). Through the detection
of common p53 mutations at codons 273, 249 and 248, Hagiwara
et al (2006) reported that p53 mutations were readily detectable
in the plasma of some smokers without cancer but not in the
plasma of non-smokers. Furthermore, they demonstrated that the
frequency of p53 mutations were associated with years of smoking.
Their results suggested that the presence of p53 mutations in
plasma DNA could reflect the exposure to carcinogens and, hence,
the chance of developing lung cancer. Their hypothesis is further
supported by a longitudinal prospective study by Gormally et al
(2006),which detected mutations of the KRAS2 and the p53 genes
in 1.2 and 3.6%, respectively, of healthy individuals. The presence
of such mutations in plasma was shown to be associated with an
increased risk of developing bladder cancer (Gormally et al, 2006).
Technically, allele-specific polymerase chain reaction (PCR) is
commonly applied for the detection of tumour-associated muta-
tions in the plasma/serum of cancer patients. This method allows
the detection of a mutated sequence present at a low concentration
among a background of wild-type sequences. However, the design
of allele-specific primers requires the sequence information of the
mutation, which can only be obtained when the primary tumour
tissue is available. Alternatively, hotspot-mutations, for example
mutations at codons 248 and 249 of the p53 gene and mutations at
the codon 12 of the KRAS gene, can be screened for in the plasma
(Gormally et al, 2006; Hagiwara et al, 2006). However, this
approach would miss the tumour-associated mutations occurring
outside the mutation hot spots and, hence, might reduce the
sensitivity of the test. Owing to these technical difficulties,
detection of tumour-associated mutations in the plasma/serum
has not been extensively used as a clinical tool for cancer detection.
The recently introduced mass spectrometry-based method, the
single allele base extension reaction (SABER), has been shown to
be particularly useful for the detection of single-nucleotide changes
in a background of wild-type sequences (Ding et al, 2004). For
example, it can effectively identify fetal-derived single-nucleotide
mutations of the beta-globin gene in the plasma of pregnant
women (Ding et al, 2004). This technique could also be applied for
the detection of tumour-associated single-nucleotide mutations in
the plasma of cancer patients.
Microsatellite alterations
Microsatellite alterations, for example, loss of heterozygosity
(LOH), are frequently demonstrated in tumour tissues. The
detection of LOH in plasma/serum was reported in 1996 in
patients suffering from small cell lung cancer (Chen et al, 1996).
The microsatellite alterations observed in the plasma were
identical to those found in the primary tumours of the respective
patients, thus indicating their tumoral origin (Chen et al, 1996).
Their findings were particularly remarkable as they indicated that
a major proportion of the circulating DNA in these cancer patients
was derived from tumour cells.
Although the presence of microsatellite alterations in plasma/
serum are more commonly found in patients with invasive
tumours, regional spread and distant metastases, these changes
have also been demonstrated in patients with localised and small
tumours (Eisenberger et al, 2006). These results indicate that the
amount of DNA released from the tumour can be substantial even
in the early stage of the disease.
Technically, as the detection rate of LOH with a single
microsatellite marker is relatively low, a panel of microsatellite
markers is usually required for the detection of LOH in tumour
tissues and plasma/serum to achieve the necessary sensitivity.
Viral DNA
Virus infection has been implicated in the pathogenesis of several
types of cancers. Thus, it is possible to use circulating viral nucleic
acids as a tumour marker for the detection and monitoring of these
virus-associated cancers. In this regard, the use of circulating
Epstein–Barr virus (EBV) DNA in nasopharyngeal carcinoma
(NPC) has been the most extensively studied and has appeared to
show much promise.
In 1999, Lo et al (1999) reported that, using real-time PCR, EBV
DNA could be detected in the plasma of 96% of NPC patients but
only in 7% of healthy subjects. In addition, they showed that the
levels of circulating EBV DNA could reflect tumour load. Patients
with advanced stage disease had a higher plasma/serum EBV
DNA than those with early disease (Lo et al, 1999). Later, it was
further demonstrated that the concentration of plasma EBV DNA
correlated with tumour load in an animal model (Chan et al,
2005a). In subsequent studies, circulating EBV DNA levels, either
at the time of diagnosis or after radiotherapy, have been shown to
be an important prognostic factor for patients’ survival, indepen-
dent of cancer stage (Lo et al, 2000; Chan et al, 2002). In view of its
prognostic value, circulating EBV DNA analysis has been proposed
to be incorporated in the risk stratification system for NPC to
complement the TNM staging system (Leung et al, 2006).
Taking advantage of the robustness of plasma EBV DNA
analysis, the elimination kinetics of tumoral DNA was studied in
NPC patients. It was shown that the median half-life for the
clearance of plasma EBV DNA after surgical resection of tumours
was only 138min (To et al, 2003). This surprisingly short half-life
of circulating EBV DNA implies that large amounts of tumoral
DNA are being constantly released into the circulation in NPC
patients. It is estimated that over 3000000 EBV genomes are being
released into the plasma of a NPC patient in each hour to maintain
a plasma EBV DNA level of 6000 EBV genome per millilitre, which
is the median level for early-stage NPC patients (Lo et al, 1999).
These findings raised the question whether active viral
replication would be responsible for producing the large amounts
of EBV DNA in the plasma of NPC patients. Through ultracen-
trifugation and DNase treatment of plasma/serum, it was shown
that circulating EBV DNA in NPC patients was not associated with
intact virions and, hence, did not support the presence of active
viral replication (Chan et al, 2003). Consistent with these data is
the fact that circulating EBV DNA molecules were mainly short
DNA fragments of less than 200bp (Chan et al, 2003).
In contrast to the detection of tumour-associated mutations and
microsatellite alterations, the detection and quantification of viral
DNA in human plasma by real-time PCR is relatively simple,
accurate and fast. The whole process from blood collection to PCR
analysis can be completed in 3h. Therefore, plasma viral DNA
analysis has a high potential for clinical application. In fact,
quantitative EBV DNA analysis has been adopted by several
centres as a routine clinical test for the detection, monitoring and
prognostication of NPC.
Hypermethylation of tumour suppressor genes
In addition to tumour-derived genetic changes, tumour-associated
epigenetic alterations have also been reported in the plasma or
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characteristic associated with the silencing of gene expression.
Hypermethylation of tumour suppressor genes is an important
mechanism in the pathogenesis of cancer and has been reported in
a wide range of cancers. To date, aberrant methylation of tumour
suppressor genes has been detected in plasma/serum of patients
suffering from many cancers (Hoque et al, 2006; Bazan et al, 2006).
Although these changes are more commonly found in patients with
more advanced disease, the simultaneous detection of aberrant
methylation of multiple tumour suppressor genes has been shown
to hold promise in detecting early cancers (Hoque et al, 2006).
There are several advantages for the detection of aberrant DNA
methylation over the genetic methods discussed above. First,
hypermethylation of multiple tumour suppressor genes are
frequently observed in cancers. Thus, the sensitivity of a cancer
detection test can be enhanced by simultaneous detection for the
hypermethylation of multiple genes. Second, using methylation-
specific PCR, the detection of aberrantly methylated sequences in
plasma can be achieved even when these sequences only constitute
a minor portion of the circulating DNA. Thus, it is expected to be
more sensitive than the detection of microsatellite alterations,
which can only be detected when the circulating DNA is mainly
comprised of tumoral DNA. Moreover, in contrast to the detection
of viral DNA that is only useful for virus-associated cancers,
hypermethylation of tumour suppressor genes is widely observed
in different types of cancers and, hence, the detection of these
changes in plasma can be applied to a wide range of cancers.
Tumour-associated RNA transcripts
Cancer cells often have distinct gene expression patterns from
normal tissues. This difference can be used diagnostically through
detecting the tumour-specific transcripts in the circulation of
cancer patients. Early studies mainly utilised these tumour-specific
mRNA as a marker for circulating tumour cells and, hence, the
detection of such transcripts in peripheral blood cells was mostly
reported in patients with distant metastases. In 1999, the detection
of tyrosinase RNA was reported in the cell-free plasma/serum of
patients suffering from melanoma (Kopreski et al, 1999). These
findings were surprising because mRNA molecules are generally
thought to be extremely labile in plasma/serum. A previous study
demonstrated that exogenous mRNA spiked into plasma would be
rapidly degraded within seconds (Tsui et al, 2002). The stability of
circulating endogenous RNA molecules was later shown to be
because of their association with small particles in plasma, which
might protect them from the degradation by circulating ribo-
nucleases (Ng et al, 2002).
The demonstration of tumour-associated RNA transcripts in
cell-free plasma/serum not only provides new targets for cancer
detection but also opens up the possibility of non-invasive gene
expression profiling for cancers. Recently, Li et al (2006)
performed gene expression profiling using serum RNA from
patients suffering from oral cancers and compared them with the
expression profiles of healthy subjects. They identified over 300
transcripts that were differentially expressed in the serum of
cancer patients and controls and they showed that the difference in
the expression patterns can accurately distinguish the two groups
(Li et al, 2006). Although this initial investigation on non-invasive
gene expression profiling using serum RNA is very exciting, these
results have to be interpreted with caution. In a previous study, it
was shown that majority of the circulating DNA was derived from
haematopoietic cells (Lui et al, 2002). Although there is no existing
information on the origin of circulating RNA, it is logical to believe
that a significant amount of circulating RNA also comes from the
haematopoietic system because of their close proximity. In this
regard, it is unclear whether the difference in gene expression
profiles between cancer patients and healthy control subjects is the
response of blood cells to a disease condition or is a direct
reflection of gene expression in the cancer cells. If it is the former
situation, the choice of control group would be very important as
this would determine whether the differences in transcription
patterns are specific for the type of cancer or they are just non-
specific changes to disease in general, for example inflammatory
responses.
Alterations in physical properties
In addition to the genetic and epigenetic changes, changes in the
physical properties of circulating nucleic acids have been observed
in cancer patients. In 1989, Stroun et al demonstrated reduced
strand stability of the circulating DNA in cancer patients (Stroun
et al, 1989). This feature was also observed in DNA extracted from
malignant tissues. Their findings represent the earliest evidence
for the presence of circulating tumour-derived DNA in cancer
patients. Recently, the size of circulating nucleic acids has also
been found to be altered in patients suffering from malignant
disease. Interestingly, the changes in integrity for RNA and DNA
are opposite. Thus, Umetani et al (2006) reported that serum DNA
integrity was significantly higher in patients with stage II, III and
IV breast cancer than in healthy females. The increase in serum
DNA integrity was also shown to predict tumour progression
(Umetani et al, 2006). On the other hand, Wong et al (2006)
reported that the integrity of circulating RNA was significantly
reduced in NPC patients (Wong et al, 2006), and the RNA integrity
was lower in patients with stage III and IV disease when compared
with stage I and II patients. Interestingly, these aberrations in RNA
integrity could be normalized after treatment (Wong et al, 2006).
The precise mechanisms leading to the alterations in circulating
nucleic acids integrity remain unclear. It has been postulated that,
in healthy subjects, circulating DNA is mainly derived from the
apoptotic cells while, in cancer patients, DNA is released from
dead cancer cells that have not gone through the normal apoptotic
process (Umetani et al, 2006). This postulation would explain why
the circulating DNA in healthy subjects is similar to the size of
nucleosomal DNA, i.e. 180bp, (Chan et al, 2004) and the size of
circulating DNA in cancer patients is longer (Umetani et al, 2006).
On the other hand, circulating RNA molecules are more
susceptible to degradation than DNA molecules and the ribo-
nuclease activity has been reported to be increased in the plasma of
cancer patients (Reddi and Holland, 1976). Therefore, the reduced
integrity of plasma RNA in cancer patients has been postulated to
be a result of accelerated RNA degradation by circulating
ribonucleases (Wong et al, 2006). Interesting, the alterations of
the integrity of circulating nucleic acids could also be observed in
other non-malignant conditions, for example pregnancy (Chan
et al, 2004).
CONCLUSIONS
The study of circulating nucleic acids for clinical diagnostic
purposes is a new but rapidly expanding field. The preliminary
reports on the detection of cancer-associated changes in the
serum/plasma of cancer patients are promising. However, there
are challenges ahead for adapting these tests for routine clinical
use. First, as most of the existing reports aimed to explore new
potential markers and involved relatively few patients, the results
of different studies using similar technologies and gene targets
could be quite different. Therefore, large-scale studies would be
necessary to address the sensitivities, specificities and the clinical
usefulness of individual markers before these tests could be used
for the management of patients. Second, there is currently no
consensus on the sample type and sample preparation protocols
for circulating nucleic acid analysis. Preanalytical factors, includ-
ing the use of anticoagulants, storage duration and conditions,
have been shown to affect the quantity and quality of circulating
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these preanalytical factors would be an important issue if large-
scale international studies are to be carried out. Third, efforts are
required to minimise the chance of contamination and, thus, false-
positive results. PCR is the most common technique used in
molecular diagnosis because of its ability in amplifying DNA and
detecting a DNA target at a low concentration. However, its high
sensitivity also poses potential risks for carry-over contamination.
The most important strategy to minimise this problem is to
physically separate the areas used for preparing the PCRs and
handling PCR products and this should be taken into considera-
tion at an early stage of establishing a molecular diagnostic
laboratory. Moreover, the use of technologies that do not require
post-PCR handling, for example real-time PCR, is also useful for
reducing the chance of contamination. Overall, we are optimistic
that circulating nucleic acid analysis would become an important
tool for the clinical management of cancer patients in the near
future.
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